Data on Adalimumab Biosimilar Confirm Equivalence of Low- and High-Concentration Formulations - AJMC.com Managed Markets Network
Research presented at EULAR 2022 demonstrated the pharmacokinetic equivalence of a low-concentration version of the adalimumab biosimilar SB5 and a high-concentration version.
While 2023 is becoming known as an important year for biosimilars because of the introduction of at least 7 adalimumab (Humira) biosimilars in the United States, there are nuances with the formulatio… [+3624 chars]
Read More
Other Stories in Business
- Sasakawa Leprosy Initiative to Boost Support for Indonesia
- JPMorgan’s Kevin Willsey retires after over 30 years at Wall Street’s largest bank
- Watch These Bitcoin Price Levels After Inauguration Day Volatility
- Epic Death's 2nd Studio Album - The Seer
- Trump gives DOGE tech modernization mission
- Trump to declare a National Energy Emergency - will enable him to use new powers
- Peter Schiff Says 'Last Night' For Biden To Sell Some Bitcoin Before Trump Takes Over: 'Let's See If He Takes Advantage Of The Opportunity'
- Newsom: 5 banks commit to mortgage relief for wildfire victims
- Farmer protest: Centre invites protesting farmers for key meeting in Chandigarh on This date - What’s on agenda?
